MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

The BRITE program and its partnerships with local universities provided Udemadu with critical hands-on training in cell culture and lab techniques. This provided a strong foundation that made his ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Both are species of cowardice.” The right cared nothing for either Jennifer or Melissa, or for their mothers. Their pain only ...

Calley Means, advisor to RFK Jr. locked horns with CNN anchor Pamela Brown and called out an alleged big pharma shill in real time for “conflicts of […] ...

The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...

Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...